141 related articles for article (PubMed ID: 22886699)
1. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
[TBL] [Abstract][Full Text] [Related]
2. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
3. Novel regulators of Fgf23 expression and mineralization in Hyp bone.
Liu S; Tang W; Fang J; Ren J; Li H; Xiao Z; Quarles LD
Mol Endocrinol; 2009 Sep; 23(9):1505-18. PubMed ID: 19556340
[TBL] [Abstract][Full Text] [Related]
4. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.
Zelenchuk LV; Hedge AM; Rowe PS
PLoS One; 2014; 9(5):e97326. PubMed ID: 24839967
[TBL] [Abstract][Full Text] [Related]
5. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.
Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO
Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276
[TBL] [Abstract][Full Text] [Related]
6. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
7. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
Karaplis AC; Bai X; Falet JP; Macica CM
Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
[TBL] [Abstract][Full Text] [Related]
8. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
Xiao L; Homer-Bouthiette C; Hurley MM
J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
[TBL] [Abstract][Full Text] [Related]
9. Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia.
Tokarz D; Martins JS; Petit ET; Lin CP; Demay MB; Liu ES
J Bone Miner Res; 2018 Mar; 33(3):499-509. PubMed ID: 29083055
[TBL] [Abstract][Full Text] [Related]
10. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
11. The role of GDF5 in regulating enthesopathy development in the Hyp mouse model of XLH.
Sorsby M; Almardini S; Alayyat A; Hughes A; Venkat S; Rahman M; Baker J; Rana R; Rosen V; Liu ES
J Bone Miner Res; 2024 Jun; ():. PubMed ID: 38836497
[TBL] [Abstract][Full Text] [Related]
12. Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis.
Sugita A; Kawai S; Hayashibara T; Amano A; Ooshima T; Michigami T; Yoshikawa H; Yoneda T
J Biol Chem; 2011 Jan; 286(4):3094-103. PubMed ID: 21075853
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin antibody improves alveolar bone quality in the
Ross R; Carpenter K; Alkhatib D; Dulion B; Guirado E; Patel S; Chen Y; George A
Res Sq; 2023 Apr; ():. PubMed ID: 37090634
[TBL] [Abstract][Full Text] [Related]
14. Multiomics profiling reveals VDR as a central regulator of mesenchymal stem cell senescence with a known association with osteoporosis after high-fat diet exposure.
Chen J; Kuang S; Cen J; Zhang Y; Shen Z; Qin W; Huang Q; Wang Z; Gao X; Huang F; Lin Z
Int J Oral Sci; 2024 May; 16(1):41. PubMed ID: 38777841
[TBL] [Abstract][Full Text] [Related]
15. FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice.
Courbon G; Kentrup D; Thomas JJ; Wang X; Tsai HH; Spindler J; Von Drasek J; Ndjonko LM; Martinez-Calle M; Lynch S; Hivert L; Wang X; Chang W; Feng JQ; David V; Martin A
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37943605
[TBL] [Abstract][Full Text] [Related]
16. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation.
Courbon G; Thomas JJ; Martinez-Calle M; Wang X; Spindler J; Von Drasek J; Hunt-Tobey B; Mehta R; Isakova T; Chang W; Creemers JWM; Ji P; Martin A; David V
Blood; 2023 Jul; 142(1):106-118. PubMed ID: 37053547
[TBL] [Abstract][Full Text] [Related]
17. PHEX
El Hakam C; Parenté A; Baraige F; Magnol L; Forestier L; Di Meo F; Blanquet V
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011266
[No Abstract] [Full Text] [Related]
18. Function of PHEX mutations p.Glu145* and p.Trp749Arg in families with X-linked hypophosphatemic rickets by the negative regulation mechanism on FGF23 promoter transcription.
Gan YM; Zhang YP; Ruan DD; Huang JB; Zhu YB; Lin XF; Xiao XP; Cheng Q; Geng ZB; Liao LS; Tang FQ; Luo JW
Cell Death Dis; 2022 Jun; 13(6):518. PubMed ID: 35654784
[TBL] [Abstract][Full Text] [Related]
19. The regulation of FGF23 under physiological and pathophysiological conditions.
Rausch S; Föller M
Pflugers Arch; 2022 Mar; 474(3):281-292. PubMed ID: 35084563
[TBL] [Abstract][Full Text] [Related]
20. Upstream Regulators of Fibroblast Growth Factor 23.
Ratsma DMA; Zillikens MC; van der Eerden BCJ
Front Endocrinol (Lausanne); 2021; 12():588096. PubMed ID: 33716961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
